{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:13:42Z","timestamp":1758845622403,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaci.2023.09.019","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:29:59Z","timestamp":1695727799000},"page":"1092-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refashioning dexpramipexole: A\u00a0new horizon in eosinophilic asthma?"],"prefix":"10.1016","volume":"152","author":[{"given":"Ruth P.","family":"Cusack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-2385","authenticated-orcid":false,"given":"Gail M.","family":"Gauvreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.09.019_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2023.09.019_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cells10040817","article-title":"Regulation of eosinophilia in asthma\u2014new therapeutic approaches for asthma treatment","volume":"10","author":"Cusack","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2023.09.019_bib3","first-page":"CD010834","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2023.09.019_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.09.019_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2023.09.019_bib6","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2023.09.019_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.09.019_bib8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2023.05.014","article-title":"Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.019_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaci.2023.09.019_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1365-2222.2009.03325.x","article-title":"Haemopoietic processes in allergic disease: eosinophil\/basophil development","volume":"39","author":"Gauvreau","year":"2009","journal-title":"Clin Exp Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923011995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923011995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:43:20Z","timestamp":1758793400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923011995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0091674923011995"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.019","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refashioning dexpramipexole: A\u00a0new horizon in eosinophilic asthma?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.05.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}